General Information of Drug (ID: DMZE3GK)

Drug Name
PF-06865571
Synonyms
Ervogastat; Ervogastat [INN]; 2186700-33-2; BSOIY5AKQW; PF-06865571; UNII-BSOIY5AKQW; 2-(5-((3-Ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-((3S)-oxolan3-yl)pyrimidine-5-carboxamide; 5-Pyrimidinecarboxamide, 2-(5-((3-ethoxy-2-pyridinyl)oxy)-3-pyridinyl)-N-((3S)-tetrahydro-3-furanyl)-; CHEMBL4760665; SCHEMBL19875384; GTPL12241; US10071992, Example 1; BDBM276750; EX-A7128; US10071992, Example 3.4; AKOS040759712; AT28030; compound 6 [PMID: 34635855]; PF06865571; 2-[5-(3-ethoxypyridin-2-yl)oxypyridin-3-yl]-N-[(3S)-oxolan-3-yl]pyrimidine-5-carboxamide; (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide
Indication
Disease Entry ICD 11 Status REF
Non-alcoholic steatohepatitis DB92.1 Phase 2 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C21H21N5O4
Canonical SMILES
CCOC1=C(N=CC=C1)OC2=CN=CC(=C2)C3=NC=C(C=N3)C(=O)NC4CCOC4
InChI
InChI=1S/C21H21N5O4/c1-2-29-18-4-3-6-23-21(18)30-17-8-14(9-22-12-17)19-24-10-15(11-25-19)20(27)26-16-5-7-28-13-16/h3-4,6,8-12,16H,2,5,7,13H2,1H3,(H,26,27)/t16-/m0/s1
InChIKey
UKBQFBRPXKGJPY-INIZCTEOSA-N
Cross-matching ID
PubChem CID
134262752
TTD ID
D8VP6R

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Diacylglycerol O-acyltransferase 2 (DGAT2) TTRHEQ4 DGAT2_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04321031) A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3. U.S.National Institutes of Health.
2 Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis. J Med Chem. 2022 Nov 24;65(22):15000-15013.